Novavax (NVAX) Receivables (2010 - 2026)
Novavax (NVAX) posted quarterly Receivables of $27.5 million for Q1 2026, down 52.8% year-over-year from $58.3 million in Q1 2025, and down 74.14% quarter-over-quarter from $106.4 million in Q4 2025.
Novavax (NVAX) Receivables (2010 - 2026) Analysis & Trends
Novavax's Receivables history runs 15 years deep, the most recent figure standing at $27.5 million for Q1 2026.
- In Q1 2026, Receivables fell 52.8% year-over-year to $27.5 million; the TTM figure through Mar 2026 stood at $27.5 million (down 52.8% YoY), while the FY2025 annual figure was $117.2 million, down 3.39% from the prior year.
- Receivables for Q1 2026 stood at $27.5 million, down from $106.4 million in the prior quarter.
- The five-year high for Receivables was $530.5 million in Q1 2022, with the low at $27.5 million in Q1 2026.
- The 5-year median for Receivables is $124.8 million (2022), against an average of $174.7 million.
- The sharpest annual moves came in 2024 and 2025: Receivables tumbled 90.91% in 2024, then soared 468.85% in 2025.
- Novavax's Receivables stood at $124.8 million in 2022, then jumped by 152.96% to $315.7 million in 2023, then sank by 61.56% to $121.4 million in 2024, then decreased by 12.33% to $106.4 million in 2025, then sank by 74.14% to $27.5 million in 2026.
- Business Quant data shows NVAX's Receivables at $27.5 million in Q1 2026, $106.4 million in Q4 2025, and $47.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | 22.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.84 Mn |
| Mar 31, 2026 | 27.51 Mn |
| Dec 31, 2025 | 106.40 Mn |
| Sep 30, 2025 | 47.05 Mn |
| Jun 30, 2025 | 239.37 Mn |
| Mar 31, 2025 | 58.29 Mn |
| Dec 31, 2024 | 121.36 Mn |
| Sep 30, 2024 | 108.84 Mn |
| Jun 30, 2024 | 42.08 Mn |
| Mar 31, 2024 | 29.26 Mn |
| Dec 31, 2023 | 315.72 Mn |
| Sep 30, 2023 | 183.93 Mn |
| Jun 30, 2023 | 463.07 Mn |
| Mar 31, 2023 | 169.38 Mn |
| Dec 31, 2022 | 124.81 Mn |
| Sep 30, 2022 | 179.65 Mn |
| Jun 30, 2022 | 223.53 Mn |
| Mar 31, 2022 | 530.46 Mn |
| Dec 31, 2021 | 490.29 Mn |
| Sep 30, 2021 | 109.96 Mn |